Acupuncture combined with western medicine for CP/CPPS: a randomized controlled trial

Objective To compare the clinical efficacy differences among acupuncture combined with western medicine,acupuncture alone and western medicine alone for chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS).Methods Ninety patients were randomly assigned into a needle-medicine group,an

Acupuncture method of“Huoxue Sanfeng,Shugan Jianpi ” for morning blood pressure in patients with cerebral infarction combined with essential hypertension: a randomized controlled trial

Objective To observe the clinical effects of acupuncture method of'Huoxue Sanfeng,Shugan Jianpi'(activating blood and eliminating wind,soothing liver and strengthening spleen)on morning blood pressure in patients with cerebral infarction combined with essential hypertension.Methods Sixty-eight patients were randomly divided into an observation group and a control group,34 cases in each one.The patients in the

Acupuncture for distal symmetric multiple peripheral neuropathy of diabetes mellitus: a randomized controlled trial

Objective To compare the clinical efficacy between acupuncture and intravenous administration of lipoic acid and alprostadil for distal symmetric multiple peripheral neuropathy of diabetes mellitus.Methods Sixty patients were randomly divided into an acupuncture group(31 cases)and a medication group(29 cases).Patients in the two groups received basic treatment to control blood sugar within a safe range.On this basis,patients in the acu-

Rhus coriaria L. increases serum apolipoprotein-A1 and high-density lipoprotein cholesterol levels： a double-blind placebo-controlled randomized clinical trial

Background： Lipid-lowering effect ofRhus coriaria L. （Rhus） has been investigated in multiple animal stud- ies with promising results. Nonetheless, its clinical efficacy has not been adequately examined. Objective： The aim of this study was to evaluate the lipid-lowering effects of Rhus among patients with hyperlipidemia. Design, setting, participants and interventions： The study was designed as a two-arm, double-blind placebo-controlled randomized clinical trial, using a parallel design. Eighty patients with primary hyper- lipidemia were randomly assigned to receive Rhus capsules or placebo for 6 weeks. Main outcome measures： The serum lipid levels, apolipoprotein-A1 （Apo-A1） and apolipoprotein-B （Apo-B） were measured. Results： Mean serum high-density lipoprotein cholesterol （HDL-C） and Apo-Al levels were significantly increased in the Rhus group, compared with the placebo group, after 6 weeks of intervention （P= 0.001）. The analysis of covariance test including age, gender, body mass index （BMI）, and smoking as co-variables revealed that the increase in HDL-C and Apo-A1 levels remained significant, and increases in HDL-C were dependent on the increase in Apo-A1 levels. No significant difference was observed between Rhus and placebo groups in terms of mean reductions in total cholesterol, low-density lipopro- tein cholesterol and triglyceride levels; however, more significant improvement was observed among obese patients （BMI≥ 30 kg/m^2）. Conclusion： The study showed significant increases in HDL-C and Apo-Al levels in response to Rhus sup- plementation in patients with hyperlipidemia. Trial registration： ClinicalTrials.gov ID： NCT02295293.

Effects of hydration in contrast-induced acute kidney injury after primary angioplasty a randomized,controlled trial

Background Intravascular volume expansion represents a beneficial measure against contrast-induced acute kidney injury （CI-AKI） in patients undergoing elective angiographic procedures. However, the efficacy of this preventive strategy has not yet been established for patients with ST-elevation-myocardial infarction （STEMI）, who are at higher risk of this complication after primary percutaneous coronary intervention （PCI）. In this randomized study we investigated the possible beneficial role of periprocedural intravenous volume expansion and we compared the efficacy of 2 different hydration strategies in patients with STEMI undergoing primary PCI.